Global Longitudinal Strain (GLS) and Speckle Tracking: Measurement Methodology, Norms, and Clinical Application — МЕДТРЕЙН Asia
Echocardiography

Global Longitudinal Strain (GLS) and Speckle Tracking: Measurement Methodology, Norms, and Clinical Application

Briefly. GLS is measured using the 2D speckle tracking method through apical views (A4C, A2C, A3C) and reflects the longitudinal systolic function of the LV. A decrease in GLS allows for the early detection of myocardial dysfunction earlier than traditional indicators (LVEF). It is applied in HFpEF, cardiomyopathies, valvular heart diseases, cardiac amyloidosis, and chemotherapy-induced cardiotoxicity.

GLS Measurement Methodology

The average global longitudinal strain (GLS) is calculated using standard apical views: apical long-axis (A3C), four-chamber (A4C), and two-chamber (A2C). The image is obtained from the apical view using the 2D mode; the units of measurement are negative percentages (−%).

Key conditions for quality registration: high image quality with stable heart rate and frame rate of 40–90 frames/s. Clear visualization of the endocardial and epicardial borders throughout the cardiac cycle is required for adequate segmental tracking in systole and diastole. Markers are placed in the basal and apical parts of the corresponding segments using automatic tracking to maintain high reproducibility.

GLS Norms

In a study on metabolic syndrome, a normal GLS was considered to be in the range of −18% to −25%. Even with a normal average GLS, a decrease in regional longitudinal strain (in the inferolateral and inferoseptal segments) can be observed. Universal GLS thresholds for specific nosologies (particularly for MetS) have not been established [to be clarified].

Clinical Application

The speckle tracking method (STE) allows for the assessment of myocardial deformation and provides additional information to traditional geometric parameters (shortening fraction, ejection fraction).

HFpEF and Diastolic Dysfunction. Although GLS is not an index of LV diastolic function, reduced GLS is among the criteria for assessing HFpEF and is associated with worse outcomes in many cardiovascular diseases accompanied by diastolic dysfunction, including cardiomyopathies and left-sided valvular heart diseases (ASE, 2025).

Aortic Regurgitation. GLS can indicate early LV dysfunction; as AR progresses, the GLS value decreases (BSE, 2025).

Cardiac Amyloidosis. GLS is part of the echocardiographic protocol for assessing transthyretin amyloidosis with calculations through A4C, A2C, A3C views.

Cardio-Oncology. In children undergoing chemotherapy, LV GLS detects subclinical LV dysfunction earlier than traditional indicators.

Metabolic Syndrome. MetS reduces the average GLS; STE can be used as a reliable method for early detection of LV myocardial damage.

Features and Limitations

Peak GLS is already part of the routine clinical process in adult patients. In children with CHD and altered ventricular geometry, STE provides reliable quantitative assessment of myocardial function as a complement to traditional parameters. Inter-vendor differences in 2D-STE GLS values should be considered, which is the subject of ongoing standardization efforts (ASE/EACVI, 2024).

Frequently asked questions

Through which views is GLS calculated?

Through three standard apical views: apical long-axis (A3C), four-chamber (A4C), and two-chamber (A2C).

What frame rate is needed for accurate measurement?

40–90 frames/s with a stable heart rate, with clear visualization of the endocardium and epicardium throughout the cardiac cycle.

What GLS values are considered normal?

In a study on metabolic syndrome, a normal GLS range was considered to be from −18% to −25%. Universal nosological thresholds in fragments have not been established.

What is the advantage of GLS over ejection fraction?

GLS/STE detects subclinical LV dysfunction earlier than traditional indicators — for example, in children after chemotherapy and in patients with MetS.

Is reduced GLS included in the criteria for HFpEF?

Yes, reduced LV GLS is one of the criteria for assessing HFpEF and is associated with worse outcomes in diseases with diastolic dysfunction (ASE, 2025).

The material is intended for specialists and does not replace clinical judgment. Threshold values are periodically reviewed — refer to the current edition of the applicable consensus.
Sources: ASE Recommendations for the Evaluation of LV Diastolic Function and HFpEF Diagnosis (2025); BSE Practical Guide to Echocardiographic Assessment of Aortic Regurgitation (2025); ASE/EACVI Clinical Applications of Strain Echocardiography — Clinical Consensus Statement (2024); Echocardiography in Metabolic Syndrome Monitoring and Management (2024); Transthyretin amyloidosis — Cardiac amyloidosis echocardiographic assessment (2023); ASE Multimodality Imaging in Children Undergoing Cancer Treatment (2023); ASE Guidelines for Performing a Comprehensive Pediatric Transthoracic Echocardiogram, Lopez et al. (2024).
View specialty courses: Echocardiography →
Спросить Alex Отвечу на любой вопрос · 24/7 · на любом языке